Boston Scientific shares drop more than 4% after major cybersecurity breach hampers order fulfillment

Traders Union
All News
Stocks
Boston Scientific slides 4.28% today

Highlights

Boston Scientific experienced a major cybersecurity incident that disrupted order fulfillment across its global operations.
The company restructured its balance sheet for a planned $15 billion subsidiary shift and distributed over $3.7 billion in dividends since 2023, while institutional investors committed about $510 million in new investments.
Shares of Boston Scientific are trading below key long-term averages, with mixed technical signals and an expected 5-day range of $46.04 to $49.36.

Investor inflows and restructuring offset cyber incident amid broad selling

Boston Scientific reported a significant cybersecurity incident that affected its worldwide operations and led to order fulfillment disruptions. The company also undertook a restructuring of its balance sheet, enabling a potential shift of $15 billion from an Irish subsidiary, and paid over $3.7 billion in dividends to parent companies since 2023. Institutional investors, including The Manufacturers Life Insurance Company and the Canada Pension Plan Investment Board, made new investments totaling approximately $510 million. These developments occurred alongside ongoing growth in revenue and profitability, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees significant near-term risk for Boston Scientific. He points out that the cybersecurity incident has disrupted operations and exposed a critical vulnerability. Institutional flows appear positive, but price action remains weak as selling persists below key averages. He warns that technical support may not hold if bearish momentum accelerates. "Until BSX restores operational confidence and reverses outflows, I would stay cautious on any rebound attempts," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, remains confident on the long-term prospects for Boston Scientific. He highlights continued institutional interest and recent dividend payouts as strong fundamental underpinnings. The restructuring unlocks significant financial flexibility, supporting growth ambitions even after headline risks. He asserts, "Despite recent volatility, the bullish structure remains intact and further growth opportunities are likely for BSX."

Jainam Mehta, market strategist, notes that BSX shows mixed momentum signals after the recent drop. He observes stabilization near the Ichimoku Kijun and 50-day moving average, suggesting possible consolidation. Price remains rangebound, but an oversold Stochastic RSI hints at a tactical rebound if $48.54 is cleared. "A contrarian long setup could emerge if buyers defend support and sentiment shifts," Mehta says.

Short-term weakness persists as mixed momentum meets technical support

BSX is trading below its 20-day moving average ($49.58) and its 200-day moving average ($68.94), while remaining above the 50-day moving average ($46.51). This reflects short-term downside momentum, medium-term support, and a bearish long-term trend. The nearest resistance is at $48.54, with immediate support at the Ichimoku Kijun ($47.69). Momentum signals are mixed: the MACD points to a strong buy, ADX is neutral, RSI stands at 53.58 (Buy), Stochastic RSI is oversold at 12.91, and CCI is neutral. Bull/Bear Power is positive at 0.15, indicating intraday buying interest with an oversold bias. The price action features early selling, stabilization near support, and divergent signals from oscillators.

Earlier, analysts noted that Boston Scientific remained under sustained bearish pressure, with technical weakness dominating the outlook. The current article adds a new dimension by incorporating the impact of a major cybersecurity incident and institutional inflows, highlighting that traders should closely monitor the $47.69 support for potential downside risk in the coming sessions.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.